Table 2 Clinicopathological characteristics of patients receiving neoadjuvant chemotherapy
Variables | Neoadjuvant chemotherapy Patients (n = 51) |
|---|---|
Menopausal status | |
 Premenopausal | 20(39.2%) |
 Postmenopausal | 31(60.8%) |
Age | |
 ≥ 50 years | 34(66.7%) |
 < 50 years | 17(33.3%) |
Hepatitis Infection | |
 No | 45(88.2%) |
 Yes | 6(11.8%) |
ALT (U/L) | 19.611 ± 2.056 |
AST (U/L) | 24.127 ± 2.088 |
Chemotherapy regimen | |
 TCb | 21(41.2%) |
 TAC | 21(41.2%) |
 AC-T | 5(9.8%) |
 TP | 2(3.9%) |
 Other | 2(3.9%) |
Histology | |
 Infiltrative ductal | 29(56.9%) |
 Infiltrative lobular | 20(39.2%) |
 Other | 2(3.9%) |
Tumor size | |
 ≥ 2 cm | 45(88.2%) |
 < 2 cm | 6(11.8%) |
Number of tumors | |
 1 | 36(70.6%) |
 > 1 | 15(29.4%) |
Grade of histology | |
 I | 15(29.4%) |
 II | 23(45.1%) |
 III | 13(25.5%) |
Lymphovascular invasion | |
 Yes | 25(49%) |
 No | 26(51%) |
ER/PR | |
 Positive | 35(68.6%) |
 Negative | 16(31.4%) |
HER2 | |
 Positive | 17(33.3%) |
 Negative | 34(66.7%) |
Ki67 | |
 ≥ 30% | 26(51%) |
 < 30% | 25(49%) |
Molecular subtype | |
 Hormone receptor positive | 35(68.6%) |
 Triple negative | 9(17.6%) |
 HER2 positive | 7(13.7%) |
N stage | |
 0 | 19(37.3%) |
 1 | 12(23.5%) |
 2 | 15(29.4%) |
 3 | 5(9.8%) |
T stage | |
 1 | 6(11.8%) |
 2 | 31(60.8%) |
 3 | 14(27.5%) |
TNM stage | |
 1 | 2(3.9%) |
 2 | 33(64.7%) |
 3 | 16(31.4%) |
Pathological response after neoadjuvant chemotherapy | |
 pPR | 23(45.1%) |
 pCR | 7(13.7%) |
 pNC | 21(41.2%) |